Vertex Pharmaceuticals (VRTX) continues to charm the market, securing a "Moderate Buy" consensus from 28 research firms.

Key Points CRISPR Therapeutics is still in its early growth stage.Summit Therapeutics has plenty of upside potential ...

Key Points Alibaba is a Chinese AI stock that's dirt cheap. Meta Platforms is making a huge bet on AI that should pay off ...

From new hires to departures, promotions and transfers, here are the latest comings and goings in the pharmaceutical industry ...

Buying $1000 In VRTX: If an investor had bought $1000 of VRTX stock 10 years ago, it would be worth $3,509.46 today based on a price of $459.81 for VRTX at the time of writing.

Vertex Pharmaceuticals Inc. closed 10.89% short of its 52-week high of $519.88, which the company achieved on November 8th.

The end of an earnings season can be a great time to discover new stocks and assess how companies are handling the current ...

Vertex Pharmaceuticals (VRTX) closed at $469.55 in the latest trading session, marking a +1.15% move from the prior day.

The participating regions are home to 84 percent of sickle cell Medicaid patients who could gain access to gene therapies under outcomes-based agreements.

States representing about 84% of Medicaid beneficiaries are participating in an initiative that enables the U.S. government ...

Why investors should use the Zacks Earnings ESP tool to help find stocks that are poised to top quarterly earnings estimates.

Vertex Pharmaceuticals (VRTX) reached $464.2 at the closing of the latest trading day, reflecting a -1.73% change compared to its last close.